TY - JOUR
T1 - Baseline Data and Measurement Instruments Reported in Observational Studies in Inflammatory Bowel Disease
T2 - Results from a Systematic Review
AU - Wong, Charlotte
AU - Van Oostrom, Joep
AU - Pittet, Valerie
AU - Bossuyt, Peter
AU - Hanzel, Jurij
AU - Samaan, Mark
AU - Tripathi, Monika
AU - Czuber-Dochan, Wladyslawa
AU - Burisch, Johan
AU - Leone, Salvatore
AU - Saldaña, Roberto
AU - Baert, Filip
AU - Kopylov, Uri
AU - Jaghult, Susanna
AU - Adamina, Michel
AU - Gecse, Krisztina
AU - Arebi, Naila
N1 - Publisher Copyright:
© 2024 The Author(s). Published by Oxford University Press on behalf of European Crohn's and Colitis Organisation.
PY - 2024/6/1
Y1 - 2024/6/1
N2 - Background: Heterogeneity in demographic and outcomes data with corresponding measurement instruments [MIs] creates barriers to data pooling and analysis. Several core outcome sets have been developed in inflammatory bowel disease [IBD] to homogenize outcomes data. A parallel Minimum Data Set [MDS] for baseline characteristics is lacking. We conducted a systematic review to develop the first MDS. Methods: A systematic review was made of observational studies from three databases [2000-2021]. Titles and abstracts were screened, full-text articles were reviewed, and data were extracted by two reviewers. Baseline data were grouped into ten domains: demographics, clinical features, disease behaviour/complications, biomarkers, endoscopy, histology, radiology, healthcare utilization and patient-reported data. Frequency of baseline data and MIs within respective domains are reported. Results: From 315 included studies [600 552 subjects], most originated from Europe [196; 62%] and North America [59; 19%], and were published between 2011 and 2021 [251; 80%]. The most frequent domains were demographics [311; 98.7%] and clinical [289; 91.7%]; 224 [71.1%] studies reported on the triad of sex [306; 97.1%], age [289; 91.7%], and disease phenotype [231; 73.3%]. Few included baseline data for radiology [19; 6%], healthcare utilization [19; 6%], and histology [17; 5.4%]. Ethnicity [19; 6%], race [17; 5.4%], and alcohol/drug consumption [6; 1.9%] were the least reported demographics. From 25 MIs for clinical disease activity, the Harvey-Bradshaw Index [n=53] and Mayo score [n=37] were most frequently used. Conclusions: Substantial variability exists in baseline population data reporting. These findings will inform a future consensus for MDS in IBD to enhance data harmonization and credibility of real-world evidence.
AB - Background: Heterogeneity in demographic and outcomes data with corresponding measurement instruments [MIs] creates barriers to data pooling and analysis. Several core outcome sets have been developed in inflammatory bowel disease [IBD] to homogenize outcomes data. A parallel Minimum Data Set [MDS] for baseline characteristics is lacking. We conducted a systematic review to develop the first MDS. Methods: A systematic review was made of observational studies from three databases [2000-2021]. Titles and abstracts were screened, full-text articles were reviewed, and data were extracted by two reviewers. Baseline data were grouped into ten domains: demographics, clinical features, disease behaviour/complications, biomarkers, endoscopy, histology, radiology, healthcare utilization and patient-reported data. Frequency of baseline data and MIs within respective domains are reported. Results: From 315 included studies [600 552 subjects], most originated from Europe [196; 62%] and North America [59; 19%], and were published between 2011 and 2021 [251; 80%]. The most frequent domains were demographics [311; 98.7%] and clinical [289; 91.7%]; 224 [71.1%] studies reported on the triad of sex [306; 97.1%], age [289; 91.7%], and disease phenotype [231; 73.3%]. Few included baseline data for radiology [19; 6%], healthcare utilization [19; 6%], and histology [17; 5.4%]. Ethnicity [19; 6%], race [17; 5.4%], and alcohol/drug consumption [6; 1.9%] were the least reported demographics. From 25 MIs for clinical disease activity, the Harvey-Bradshaw Index [n=53] and Mayo score [n=37] were most frequently used. Conclusions: Substantial variability exists in baseline population data reporting. These findings will inform a future consensus for MDS in IBD to enhance data harmonization and credibility of real-world evidence.
KW - core outcome set
KW - Inflammatory bowel disease
KW - measurement instruments
KW - minimum dataset
KW - real-world evidence
UR - https://www.scopus.com/pages/publications/85195225563
U2 - 10.1093/ecco-jcc/jjae004
DO - 10.1093/ecco-jcc/jjae004
M3 - Review
C2 - 38214470
AN - SCOPUS:85195225563
SN - 1873-9946
VL - 18
SP - 875
EP - 884
JO - Journal of Crohn's and Colitis
JF - Journal of Crohn's and Colitis
IS - 6
ER -